ABSTRACT
OBJECTIVE: This study was performed to compare postoperative adjuvant paclitaxel and platinum (TC) chemotherapy and radiation therapy in women with uterine endometrial carcinoma. METHODS: Total one hundred five patients were entered into this trial. Non-endometrioid histologic subtypes such as serous, clear cell and small cell types were excluded from the study because they have different biological potentials. Of 58 assessable patients, who were needed adjuvant treatment according to surgico-pathologic reports, after surgery, 34 were received TC chemotherapy and 24 were received radiation therapy. Chemotherapy consisted of paclitaxel 175 mg/m2 and carboplatin AUC 5 (or cisplatin 50 mg/m2) every 3 weeks for 3 or 6 cycles. Irradiation dosage was 4,500~5,040 cGy in 28 fractions. RESULTS: In 58 evaluated patients, median follow-up time was 40.3 months (range 7~64 months). The 5-year overall survival and 5-year disease-free survival were 91.3% and 91.0% in 34 patients treated with TC chemotherapy, and 91.4% and 82.8% in 24 cases who treated with radiation therapy, however, there were no significant difference (P=0.646, P=0.129). The most common adverse effect of TC chemotherapy was hematologic toxicity, which was manageable conservatively. The serious gastrointestinal complication of radiotherapy was noted in 5 patients (20.8%), three of these patients were received another bowel surgery, such as ileo-cecal bypass, however, symptoms were persisted after surgery. CONCLUSIONS: These data suggest that postoperative adjuvant TC chemotherapy is a promising treatment which could be substituted for radiation therapy, with major activity and a acceptable toxicity profile for the treatment of uterine endometrial carcinoma.
Subject(s)
Female , Humans , Area Under Curve , Carboplatin , Chemotherapy, Adjuvant , Cisplatin , Disease-Free Survival , Endometrial Neoplasms , Follow-Up Studies , Paclitaxel , Platinum , Radiotherapy, AdjuvantABSTRACT
PLC-gamma1 plays a central role in the signal transduction for cellular activity, such as proliferation and differentiation. However, the significance of their expressions in endometrial cancer is yet to be determined. The current study examined the expression prevalence of phospholipase C-gamma1(PLC-gamma1) , and studied its relationship with p53 expression in endometrial carcinomas of varying stages and grades. Expressions of PLC-gamma1 and p53 were determined using immunohistochemical taining of paraffin embedded tissues from 21 endometrial specimens; Specimens included 10 cases of grade I, 8 cases of grade II, and 3 cases of grade III lesions. While there were few PLC-gamma1 expressions in the control group, 60% (6/10) of grade I carcinomas showed obvious PLC-gamma1 expression, 50%, and 30% of Grade II and III cases did respectively. In addition, PLC-gamma1 expression was restricted to the tumor lesions and the intensity of the PLC-lambda1 was the strongest in well differentiated cancers. P53 expression was identified in 7 of 21 (33%) cases, and there was no relationship between PLC-gamma1 expression and p53 overexpression. Our studies revealed that levels of PLC-gamma1 play important roles in the occurrence of ndometrial carcinomas, though factors that might influence them still remain obscure. And also further studies about correlation between PLC-gamma1 and p53 are needed to elucidate that in tumorigenesis.